Answers are grounded in this paper and cite their sources.
A prospective trial shows lenvatinib, chemoembolization, and PD-1 blockade enable salvage surgery in unresectable liver cancer, suggesting a viable conversion strategy.
Most patients with hepatocellular carcinoma (HCC) are diagnosed with intermediate- or advanced-stage disease1 but resection with clear margins offers the best opportunity for cure2. Conversion therapy (to make the tumour resectable) has not been used routinely because of lack of evidence3. The present study described the process of conceptualization, preparation, and implementation of a novel conversion therapy strategy using the IDEAL (Idea, Development, Exploration, Assessment, Long-term study) framework4. This prospective, single-arm, single-centre, IDEAL phase 1 study (10 August 2020 and 10 January 2021) was approved by the ethics committee of West China Hospital (2020-836). It was the initial component of a prospective clinical trial that was registered with ClinicalTrials.gov (NCT04997850). Salvage liver resection after a lenvatinib plus transarterial chemoembolization (TACE) and programmed cell death protein 1 (PD-1) inhibitor (LEN-TAP) strategy for unresectable HCC (uHCC) was initiated after several meetings of the multidisciplinary team for HCC of West China Hospital. Details of the conceptualization of LEN-TAP, patient selection and study design, institutional review board approvals and patient consent, prospective database, LEN-TAP regimen, safeguards, efficacy assessment, and salvage liver resection after LEN-TAP are available in the supplementary material. Six of seven patients had advanced HCC with macrovascular invasion. Baseline characteristics are summarized in Table S1. After LEN-TAP therapy, a complete response was recorded in two patients, a partial response in four, and one patient had progressive disease (Table S2 and Fig. S1). Four of six patients who achieved a partial or complete response successfully underwent salvage liver resection. Images obtained before LEN-TAP therapy and before surgery, and photographs of resected specimens are shown in Fig. 1. The other two patients with a partial response did not undergo salvage liver resection because of decompensated liver function (ascites, 25.4 per cent indocyanine green retention at 15 min) and cavernous transformation of the portal vein. Images showing radiological changes and resected specimens for patients who received LEN-TAP therapy a Four patients successfully underwent salvage liver resection. The target lesion and tumour thrombus (indicated by arrows) shrank after treatment. b Three patients did not receive salvage liver resection. A new lesion (indicated by arrow) was found in patient 2 after treatment, target lesion and tumour thrombus (indicated by arrows) and an ongoing partial response was recorded in patients 1 and 4. LEN-TAP, lenvatinib, transarterial chemoembolization, and programmed cell death protein 1 inhibitor therapy. After a median follow-up of 19 months, one patient had died from HCC progression, whereas the other patients remained alive without recurrence or progression (Fig. 2). Adverse events after LEN-TAP therapy and perioperative outcomes for patients who received salvage liver resection are shown in Tables S3 and S4. Survival among patients who received LEN-TAP therapy a Overall (OS) and progression-free (PFS) survival time for patients who did not receive salvage liver resection. b Programmed cell death protein 1 (PD-1) cycles before surgery, pathological response, and survival time for patients who successfully underwent salvage liver resection. LEN-TAP, lenvatinib, transarterial chemoembolization, and PD-1 inhibitor therapy; RFS, recurrence-free survival; pMR, pathological major response; pCR, pathological complete response. Two specific goals of safety and preliminary efficacy of LEN-TAP conversion therapy were achieved in this IDEAL phase 1 study. Figure S2 summarizes the process for evolution of the LEN-TAP strategy. The IDEAL framework provides methodological guidance for rigorous stepwise complex therapeutic interventions5. LEN-TAP conversion therapy could efficiently convert uHCC to resectable disease with manageable adverse events, and salvage liver resection could offer a favourable survival benefit. Clinical investigators have explored the use of lenvatinib, a tyrosine kinase inhibitor, for patients with uHCC6,7. Their results indicated that a survival benefit might be provided by R0 resection after lenvatinib therapy, but with a low efficacy of conversion. Even though TACE was not recommended for patients with advanced HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging system, some studies8–11 found TACE to be feasible and effective in such patients. Moreover, TACE was recommended for selected patients with advanced HCC in Japanese and Chinese guidelines12–14. In the LAUNCH trial15, the median overall survival time reached 17.8 months with lenvatinib and TACE. Other studies16–18 have reported positive results. A retrospective study19 regarding conversion therapy comprising lenvatinib, TACE, and PD-1 inhibitors reported salvage resection in 29 of 62 patients with uHCC after this triple therapy. The IDEAL framework here allowed introduction of salvage liver resection after LEN-TAP strategy in an evidence-based manner without exposing patients to unacceptable risk. The authors have no funding to declare. W. Peng and X. Zhang contributed equally to this work . W. Peng reports receiving lecture fees from Bayer, Merk, Roche, Hengrui, SciClone. X. Zhang received grant support from Innovent, Eisai and lecture fees from Bayer, Merk, Roche, Hengrui. C. Li received consulting fees from Bayer and Merk. T. Wen reports receiving grant support from AstraZeneca, Zelgen, Merk, Roche, Eisai and Innovent, advisory board fees and lecture fees from Bayer, Merk, Roche, Hengrui. No other potential conflict of interest was reported. Supplementary material is available at BJS online. The raw data for this article is available upon request.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: